Unveiling the Prevalence and Surgical Burden of Neurocristopathies: A Scoping Review and Statistical Analysis

The prevalence, clinical burden, impact on quality of life, and multidisciplinary treatment planning of Neurocristopathies (NCPs), disorders arising from aberrant development of neural crest cells (NCCs), remain obscure. NCCs are a pleistopotent embryonic stem cell population with diverse progeny of cell types ranging from craniofacial skeleton to cardiac outflow tract, peripheral nervous system, chromaffin cells, melanocytes etc. Given the broad range of neural crest derivatives, patients often present with complex, multisystem manifestations. However, these diverse symptoms may be overlooked, resulting in surgical planning that addresses only a single manifestation at a time rather than integrating the patient's full clinical presentation into treatment decisions.

This scoping review with statistical analysis identified 92 distinct NCPs to quantify prevalence, anatomical defect patterns, cell type of origin and surgical management needs across craniofacial and non-craniofacial phenotypes.

When scaled to global birth statistics, NCPs accounted for ~4.24% of all live births, indicating that more than half (61%) of serious congenital anomalies are neurocristopathy in origin, greatly exceeding prior estimates. These primarily consisted of craniofacial, conotruncal, and peripheral nervous system defects. Plastic and reconstructive surgery (PRS) (which significantly overlap in procedures of Oral & Maxillofacial Surgery in the Craniofacial complex) emerged as a central clinical modality: 61 NCPs (66.3%) required PRS/OMFS, and nearly 100% of craniofacial bone and cartilage anomalies required functional reconstruction. Mandibular reconstruction (37%) and cleft lip/palate repair (37%) represented the most common interventions, with midface advancement, ear reconstruction, and cranial vault remodeling also frequently required. Chi-square analysis demonstrated a strong association between anatomical category and likelihood of PRS intervention (χ² = 52.91, p < 0.001), with craniofacial involvement conferring the highest risk.

These findings establish NCPs as a major, underrecognized driver of congenital disease burden and demonstrate the critical role of PRS in restoring function and form across neurocristopathy phenotypes.